Phase III failure for Aranesp in heart failure
This article was originally published in Scrip
Executive Summary
A Phase III trial of Amgen's Aranesp (darbepoetin alfa) to evaluate whether the treatment of anemia could improve morbidity and mortality in systolic heart failure patients has failed to meet its primary endpoint.